Xeltis’ restorative pulmonary heart valve is featuring at the prestigious Pulmonary Heart Valve Global Multidisciplinary Workshop organized by the US Food and Drug Administration (FDA) in conjunction with the Heart Valve Collaboratory on October 14 and 15, 2022.
Doctor David Morales, Cincinnati Children’s Hospital and one of the investigators in the Xplore2 pivotal trial of Xeltis’ pulmonary valve, provided an update on the study yesterday. Xeltis CTO, Martijn Cox, will illustrate the pulmonary valve program during a specific session on innovative technology today.
“We are humbled to be invited among global leaders in pulmonary heart valve treatment to contribute to potential solutions,” said Martijn Cox.
